Low expression of tyrosine-protein phosphatase nonreceptor type 12 is associated with lymph node metastasis and poor prognosis in operable triple-negative breast cancer

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 1, 2013, Pages 287-292

  Wu, Min Qing ^a   Hu, Pan ^b   Gao, Jie ^a   Wei, Wei Dong ^a   Xiao, Xiang Sheng ^a   Tang, Hai Lin ^a   Li, Xing ^a   Ge, Qi Dong ^a   Jia, Wei Hua ^a   Liu, Ren Bin ^b   Xie, Xiao Ming ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Breast cancer; Immunohistochemistry; Prognosis; PTPN12; Triple negative breast cancer

Indexed keywords

EID: 84877110148     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.1.287     Document Type: Article

References (32)

1. Anders CK, Carey LA (2009). Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer, 9, S73-81.
2. Andersen JN, Jansen PG, Echwald SM, et al (2004). A genomic perspective on protein tyrosine phosphatases: gene structure, pseudogenes, and genetic disease linkage. Faseb J, 18, 8-30.
3. Angers-Loustau A, Cote JF, Charest A, et al (1999). Protein tyrosine phosphatase-PEST regulates focal adhesion disassembly, migration, and cytokinesis in fibroblasts. J Cell Biol, 144, 1019-31.
4. Bocker W (2002) WHO classification of breast tumors and tumors of the female genital organs: pathology and genetics. Verh Dtsch Ges Pathol, 86, 116-9 (in German).
5. Brady-West DC, McGrowder DA (2011). Triple negative breast cancer: therapeutic and prognostic implications. Asian Pac J Cancer Prev, 12, 2139-43
6. Cao X, Li Y, Luo RZ, et al (2012). Tyrosine-protein phosphatase nonreceptor type 12 is a novel prognostic biomarker for esophageal squamous cell carcinoma. Ann Thorac Surg, 93, 1674-80.
7. Carey LA, Perou CM, Livasy CA, et al (2006). Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 295, 2492-502.
8. Connolly JL (2006). Changes and problematic areas in interpretation of the AJCC Cancer Staging Manual, 6th Edition, for breast cancer. Arch Pathol Lab Med, 130, 287-91.
9. Davidson D, Shi X, Zhong MC, et al (2010). The phosphatase PTP-PEST promotes secondary T cell responses by dephosphorylating the protein tyrosine kinase Pyk2. Immunity, 33, 167-80.
10. DeSantis C, Siegel R, Bandi P, et al (2011). Breast cancer statistics, 2011. CA Cancer J Clin, 61, 409-18.
11. Espejo R, Rengifo-Cam W, Schaller MD, et al (2010). PTP-PEST controls motility, adherens junction assembly, and Rho GTPase activity in colon cancer cells. Am J Physiol Cell Physiol, 299, C454-63.
12. Friedrichs K, Gluba S, Eidtmann H, et al (1993). Overexpression of p53 and prognosis in breast cancer. Cancer, 72, 3641-7
13. Galgano MT, Hampton GM, Frierson HJ (2006) Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol, 19, 847-53.
14. Garton AJ, Burnham MR, Bouton AH, et al (1997). Association of PTP-PEST with the SH3 domain of p130cas; a novel mechanism of protein tyrosine phosphatase substrate recognition. Oncogene, 15, 877-85.
15. He J, Peng R, Yuan Z, et al (2012). Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol, 29, 406-10.
16. Hsu JL, Huang SY, Chow NH, et al (2003). Stable-isotope dimethyl labeling for quantitative proteomics. Anal Chem,75, 6843-52.
17. Hunter T (2009). Tyrosine phosphorylation: thirty years and counting. Curr Opin Cell Biol, 21, 140-6.
18. Kaplan HG, Malmgren JA, Atwood M (2009). T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy. Breast J, 15, 454-60.
19. Kaplan HG, Malmgren JA (2008). Impact of triple negative phenotype on breast cancer prognosis. Breast J, 14, 456-63.
20. Kim MJ, Ro JY, Ahn SH, et al (2006). Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol, 37, 1217-26.
21. Kwong A, Wong LP, Wong HN, et al (2009). A BRCA2 founder mutation and seven novel deleterious BRCA mutations in southern Chinese women with breast and ovarian cancer. Breast Cancer Res Treat, 117, 683-6.
22. Ma KK, Chau WW, Wong CH, et al (2012). Triple negative status is a poor prognostic indicator in Chinese women with breast cancer: a ten year review. Asian Pac J Cancer Prev, 13, 2109-14.
23. Nielsen TO, Hsu FD, Jensen K, et al (2004). Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res, 10, 5367-74.
24. Rakha EA, Reis-Filho JS, Ellis IO (2008). Basal-like breast cancer: a critical review. J Clin Oncol, 26, 2568-81.
25. Rhee I, Veillette A (2012). Protein tyrosine phosphatases in lymphocyte activation and autoimmunity. Nat Immunol, 13, 439-47.
26. Streit S, Ruhe JE, Knyazev P, et al (2006). PTP-PEST phosphatase variations in human cancer. Cancer Genet Cytogenet, 170, 48-53.
27. Sun T, Aceto N, Meerbrey KL, et al (2011). Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell, 144, 703-18.
28. Tonks NK (2006). Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol, 7, 833-46.
29. Villa-Moruzzi E (2011). Tyrosine phosphatases in the HER2-directed motility of ovarian cancer cells: Involvement of PTPN12, ERK5 and FAK. Anal Cell Pathol (Amst), 34, 101-12.
30. Westbrook TF, Hu G, Ang XL, et al (2008). SCFbeta-TRCP controls oncogenic transformation and neural differentiation through REST degradation. Nature, 452, 370-4.
31. Wu M, Wei W, Xiao X, et al (2012). Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer. Med Oncol, 29, 3240-9.
32. Zheng Y, Yang W, Xia Y, et al (2011). Ras-induced and extracellular signal-regulated kinase 1 and 2 phosphorylation-dependent isomerization of protein tyrosine phosphatase (PTP)-PEST by PIN1 promotes FAK dephosphorylation by PTP-PEST. Mol Cell Biol, 31, 4258-69.